By Debashis Ghosh, TCS in the International Clinical Trials Magazine
As life sciences firms increasingly look to BRIC countries for strategic growth, a granular assessment of the drivers and constraints in each market – including revenue, savings and innovation potential – is needed to support the business case.
In this article, Debashis Ghosh discusses how TCS’ Emerging Markets Index (EMI) model helps life sciences firms assess the viability of doing business in emerging markets like the BRIC countries. The EMI examines three complementary yet distinct perspectives – revenue, savings and innovation. Using this model, companies can understand the opportunities, challenges and risks in each of these markets and make more informed decisions.